Atlas Capital Advisors LLC Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Atlas Capital Advisors LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 98.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 151 shares of the biopharmaceutical company’s stock after selling 8,334 shares during the period. Atlas Capital Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $145,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of REGN. Federated Hermes Inc. increased its stake in Regeneron Pharmaceuticals by 6.1% during the 3rd quarter. Federated Hermes Inc. now owns 2,796 shares of the biopharmaceutical company’s stock worth $2,301,000 after buying an additional 160 shares in the last quarter. O Shaughnessy Asset Management LLC grew its position in shares of Regeneron Pharmaceuticals by 80.2% in the third quarter. O Shaughnessy Asset Management LLC now owns 5,737 shares of the biopharmaceutical company’s stock valued at $4,721,000 after purchasing an additional 2,553 shares in the last quarter. Mutual Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 153.0% in the third quarter. Mutual Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $1,690,000 after purchasing an additional 1,242 shares in the last quarter. Mather Group LLC. grew its position in Regeneron Pharmaceuticals by 13.6% in the third quarter. Mather Group LLC. now owns 1,059 shares of the biopharmaceutical company’s stock worth $872,000 after acquiring an additional 127 shares during the period. Finally, Synovus Financial Corp grew its position in Regeneron Pharmaceuticals by 4.0% in the third quarter. Synovus Financial Corp now owns 1,657 shares of the biopharmaceutical company’s stock worth $1,364,000 after acquiring an additional 63 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.2 %

Regeneron Pharmaceuticals stock opened at $1,069.16 on Thursday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $1,081.17. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market cap of $117.81 billion, a PE ratio of 31.59, a P/E/G ratio of 2.21 and a beta of 0.13. The stock’s fifty day moving average is $974.69 and its two-hundred day moving average is $947.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The business had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the transaction, the director now owns 1,382 shares of the company’s stock, valued at $1,397,202. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,347,256.52. The disclosure for this sale can be found here. Insiders have sold a total of 61,971 shares of company stock worth $61,217,654 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on REGN shares. Argus increased their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial restated a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. Bank of America upped their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Finally, UBS Group upped their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,008.96.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.